Development of a diagnostic technology to predict the efficacy of immune checkpoint inhibitors
First written in FY2019-Q1. 2 of 4 entries say "Advanced", first in FY2020-Q2. Latest entry: FY2025-H1.
No other company in this theme has enough history to compare yet.
- FY2025-H1AdvancedAnnual report
「In April 2024, research groups from Kindai University and Kyoto University, through joint research with the company, demonstrated the potential to predict the efficacy of anti-PD-1 antibodies, including Opdivo (generic name: nivolumab), for non-small cell lung cancer using “immune checkpoint-related factors” in blood.」
Joint research with Kindai University and Kyoto University indicated the potential to predict the efficacy of anti-PD-1 antibodies from immune checkpoint-related factors in blood as part of diagnostic testing to predict the efficacy of immune checkpoint inhibitors. - FY2020-Q2AdvancedAnnual report
「Since 2013, our Company and Specially Appointed Professor Tasuku Honjo (本庶 佑) of the Institute for Advanced Study at Kyoto University, a national university corporation, have jointly conducted R&D aimed at creating new diagnostic technologies in oncology and immune diseases. We recently established a fully automated assay method for soluble immune checkpoint molecules (sPD-1, sPD-L1 and sCTLA-4) using the research-use fully automated high-sensitivity immunoassay analyzer HI-1000, and began offering contract research services using this method in September 2019. This assay method may become a new diagnostic method for cancer immunotherapy and various autoimmune diseases, contributing to the realization of personalized medicine.」
For diagnostic technology related to immune checkpoint inhibitors and other treatments, developed a fully automated method for measuring soluble immune checkpoint molecules and launched contract research services. - FY2019-Q2RestatedAnnual report
「In April 2018, the company and Immunity Research Co., Ltd. entered into an agreement under which Immunity Research, which held the exclusive ordinary license to the patent titled “Method for Predicting the Efficacy of Immune Checkpoint Inhibitors in Advance Using a Blood Test,” granted the company a sublicense. The company is developing diagnostic technology based on this patent with the aim of predicting the efficacy of immune checkpoint inhibitors.」
Restates the policy of developing diagnostic technology to predict the efficacy of immune checkpoint inhibitors as part of its research and development activities. - FY2019-Q1First statedAnnual report
「In April 2018, the company and Immunity Research Co., Ltd. entered into an agreement under which Immunity Research, which held the exclusive ordinary license to the patent titled “Method for Predicting the Efficacy of Immune Checkpoint Inhibitors in Advance Using a Blood Test,” granted the company a sublicense. The company is developing diagnostic technology based on this patent with the aim of predicting the efficacy of immune checkpoint inhibitors.」
Obtained a sublicense to the patent from Immunity Research Co., Ltd. and is working to develop diagnostic technology for predicting the efficacy of immune checkpoint inhibitors in advance.